Gastro-retentive dosage form for improving bioavailability of cefpodoxime proxetil in rats

Yakugaku Zasshi

Volumn 128, Issue 3, 2008, Pages 439-445

  Kakumanu, Vasu Kumar ^a   Arora, Vinod Kumar ^b   Bansal, Arvind Kumar ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Cefpodoxime acid; Cefpodoxime proxetil; Gastro retentive; Metabolism; Pharmacokinetics; Stability

Indexed keywords

CEFPODOXIME PROXETIL; PRODRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; GASTROINTESTINAL TRACT; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; MALE; NONHUMAN; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CEFTIZOXIME; DOSAGE FORMS; DRUG STABILITY; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 40449139333     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.439     Document Type: Article

References (27)

1. Crauste-Manciet S., Huneau J. F., Decroix M. O., Tome D., Chaumeil J. C, Int. J. Pharm., 149, 241-249 (1997).
2. Kobayashi S., Oguchi K., Uchida E., Yasuhara H., Sakamoto K., Sekine M., Sasahara K., Chemotherapy, 36, 200-214 (1988).
3. Komai T., Kawai K., Tsubaki H., Tokui T., Kinoshita T., Tanaka M., Chemotherapy, 36, 229-240 (1988).
4. Hughes G. S., Heald D. L., Barker K. B., Patel R. K., Euler A. R., Clin. Pharmacol. Thera., 46, 674-685 (1989).
5. Borin M. T., Drugs, 42, 13-21 (1991).
6. Hamamura T., Kusai A., Nishimura K., S.T.P. Pharm. Sci., 5, 324-331 (1995).
7. Hamamura T., Ohtani T., Kusai A., Nishimura K., S.T.P. Pharm. Sci., 5, 332-338 (1995).
8. Hamamura T., Terashima H., Ohtani T., Mori Y., Seta Y., Kusai A., Sasahara K., Nishimura K., Yakuzaigaku, 55, 175-182 (1995).
9. Kakumanu V. K., Arora V. K. Bansal A. K., Int. J. Pharm., 317, 155-160 (2006).
10. Kakumanu V. K., Arora V. A., Bansal A. B, J. Chrom. B., 835, 16-20 (2006).
11. Kasim N. A., Whitehouse M., Ramachandran C., Bermejo M., Lennernas H., Hussain A. S., Junginger H. E., Stavchansky S. A., Midha K. K., Shah V. P., Amidon G. L., Mole. Pharm., 1, 85-96 (2004).
12. Lindenberg M., Kopp S., Dressman J., Eur. J. Pharm. Biopharm., 58, 265-278 (2004).
13. Rinaki E., Valsami G., Macheras P., Pharm. Res., 20, 1917-1925 (2004).
14. Yu L. X., Pharm. Res., 16, 1883-1887 (1999).
15. Narawane M., Podder S. K., Bundgaard H., Lee V. H., J. Drug. Target., 1, 29-39 (1993).
16. Augustijns P., Annaert P., Heylen P., Van den Mooter G., Kinget R., Int. J. Pharm., 166, 45-53 (1998).
17. Inoue M., Morikawa M., Tsuboi M., Yamada T., Sugiura M., Jpn. J. Pharmacol., 29, 17-25 (1979).
18. Inoue M., Morikawa M., Tsuboi M., Ito Y., Sugiura M., Jpn. J. Pharmacol., 30, 529-535 (1980).
19. Van Gelder J., Shafiee M., De Clercq E., Pennickx F., Van den Mooter G., Kinget R., Augustijns P., Int. J. Pharm., 205, 93-100 (2000).
20. Ichikawa M., Watanable S., Miyake Y., J. Pharm. Sci., 80, 1062-1066 (1991).
21. Ichikawa M., Kato T., Kawahara M., Watanabe S., Kayano M., J. Pharm. Sci., 80, 1153-1156 (1991).
22. Singh B. N., Kim K. H., J. Control. Rel., 63, 235-259 (2000).
23. Nicholas G., Crauste-Manciet S., Farinotti R., Brossard D., Int. J. Pharm., 263, 165-171 (2003).
24. Koup J. R., Dubach U. C., Brandt R., Wyss R., Stoeckel K., Antimicrob. Agents Chemother., 32, 573-579 (1988).
25. Darkes M. J. Plosker G. L., Drugs, 62, 319-336 (2002).
26. Finn A., Straugun A., Meyer M., Chubb J., Biopharm. Drug Dispos., 8, 519-526 (1987).
27. Williams P. Harding S. M., J. Antimicrob. Chem., 13, 191-196 (1984).